Should cytology be an acceptable means of diagnosing malignant mesothelioma?

Cytopathology

Volumn 22, Issue 1, 2011, Pages 3-4

  Sheaff, M ^a,b  

^a BARTS HEALTH NHS TRUST   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ASBESTOS; CARCINOEMBRYONIC ANTIGEN; THYROID TRANSCRIPTION FACTOR 1; TUMOR MARKER;

CANCER INVASION; CYTOLOGY; CYTOPATHOLOGY; DIFFERENTIAL DIAGNOSIS; EDITORIAL; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MALIGNANT MESOTHELIOMA; OCCUPATIONAL EXPOSURE; PRIORITY JOURNAL; PROGNOSIS; RADIODIAGNOSIS;

CELL TRANSFORMATION, NEOPLASTIC; CYTODIAGNOSIS; DIAGNOSIS, DIFFERENTIAL; FORECASTING; HUMANS; MESOTHELIOMA; NEOPLASM METASTASIS;

EID: 78651234936     PISSN: 09565507     EISSN: 13652303     Source Type: Journal    
DOI: 10.1111/j.1365-2303.2010.00840.x     Document Type: Editorial

References (10)

1. Davidson B. The diagnostic and molecular characteristics of malignant mesothelioma and ovarian/peritoneal serous carcinoma. Cytopathology 2011;21:5-21.
2. Whitaker D. The cytology of malignant mesothelioma. Cytopathology 2000;11:139-51.
3. British Thoracic Society Standards of Care Committee. BTS statement on malignant mesothelioma in the UK, 2007. Thorax 2007;62(Suppl. 2):ii1-19.
4. Roberts ME, Neville E, Berrisford RG et al. Management of a malignant pleural effusion: British Thoracic Society Pleural Disease Guideline 2010. Thorax 2010;65(Suppl. 2):ii32-40.
5. Scherpereel A, Astoul P, Baas P et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J 2010;35:479-95.
6. Husain AN, Colby TV, Ordonez NG et al. Guidelines for the pathological diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 2009;133:1317-31.
7. American Thoracic Society. Management of malignant pleural effusions. Am J Respir Crit Care Med 2000;162:1987-2001.
8. Attanoos RL, Griffin A, Gibbs AR. The use of immunohistochemistry in distinguishing reactive from neopalstic mesothelial. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor, p-glycoprotein and Bcl-2. Histopathology 2003;43:231-8.
9. Nissan A, Stodjadinovic A, Garofalo A, Esquivel J, Piso P. Evidence-based medicine in the treatment of peritoneal carcinomatosis: past, present and future. J Surg Oncol 2009;100:335-44.
10. Chandra A, Cross P, Giles T et al. The BSCC Code of Practice - exfoliative cytopathology (excluding gynaecological cytopathology). Cytopathology 2009;20:211-23.